WEKO3
アイテム
{"_buckets": {"deposit": "954c5f82-4540-4390-b608-0584976124a5"}, "_deposit": {"created_by": 6, "id": "27793", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "27793"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00027793", "sets": ["26"]}, "author_link": ["123641", "123636", "123640", "123638", "123637", "123639"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "175346662211372", "bibliographicVolumeNumber": "16", "bibliographic_titles": [{"bibliographic_title": "Therapeutic Advances in Respiratory Disease"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objective: Radiation-induced lung injury (RILI) is one of the serious complications of radiotherapy. We have recently demonstrated that nicaraven can effectively mitigate RILI in healthy mice. Here, we further tried to optimize the dose and time of nicaraven administration for alleviating the side effects of radiotherapy in tumor-bearing mice.\nMethods and results: A subcutaneous tumor model was established in the back of the chest in C57BL/6N mice by injecting Lewis lung cancer cells. Therapeutic thoracic irradiations were done, and placebo or different doses of nicaraven (20, 50, 100 mg/kg) were administrated intraperitoneally pre-irradiation (at almost 5–10 min before irradiation) or post-irradiation (within 5 min after irradiation). Mice that received radiotherapy and nicaraven were sacrificed on the 30th day, but control mice were sacrificed on the 15th day. Serum and lung tissues were collected for evaluation. Nicaraven significantly decreased the level of CCL8, but did not clearly change the levels of 8-OHdG, TGF-β, IL-1β, and IL-6 in serum. Besides these, nicaraven effectively decreased the levels of TGF-β, IL-1β, and SOD2 in the lungs, especially by post-irradiation administration with the dose of 20 mg/kg. Although there was no significant difference, the expression of SOD1, 53BP1, and caspase 3 was detected lower in the lungs of mice received nicaraven post-irradiation than that of pre-irradiation.\nConclusion: According to our data, the administration of nicaraven at a relatively low dose soon after radiotherapy will be recommended for attenuating the side effects of radiotherapy.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Therapeutic Advances in Respiratory Disease, 16, art.no. 175346662211372; 2022", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "SAGE Publications Ltd"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1177/17534666221137277", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Author(s), 2022. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage)."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1753-4666", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Xu, Yong"}], "nameIdentifiers": [{"nameIdentifier": "123636", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Abdelghany, Lina"}], "nameIdentifiers": [{"nameIdentifier": "123637", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sekiya, Reiko"}], "nameIdentifiers": [{"nameIdentifier": "123638", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhai, Da"}], "nameIdentifiers": [{"nameIdentifier": "123639", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Jingu, Keiichi"}], "nameIdentifiers": [{"nameIdentifier": "123640", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Li, Tao-Sheng"}], "nameIdentifiers": [{"nameIdentifier": "123641", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2022-12-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "TARD16.pdf", "filesize": [{"value": "2.3 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2300000.0, "url": {"label": "TARD16.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/27793/files/TARD16.pdf"}, "version_id": "96224808-bd28-4fb8-b05d-9678640b06b1"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "DNA damage", "subitem_subject_scheme": "Other"}, {"subitem_subject": "fibrosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "inflammatory response", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lung injury", "subitem_subject_scheme": "Other"}, {"subitem_subject": "radiation", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Optimization on the dose and time of nicaraven administration for mitigating the side effects of radiotherapy in a preclinical tumor-bearing mouse model", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Optimization on the dose and time of nicaraven administration for mitigating the side effects of radiotherapy in a preclinical tumor-bearing mouse model"}]}, "item_type_id": "2", "owner": "6", "path": ["26"], "permalink_uri": "http://hdl.handle.net/10069/00041927", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-12-05"}, "publish_date": "2022-12-05", "publish_status": "0", "recid": "27793", "relation": {}, "relation_version_is_last": true, "title": ["Optimization on the dose and time of nicaraven administration for mitigating the side effects of radiotherapy in a preclinical tumor-bearing mouse model"], "weko_shared_id": -1}
Optimization on the dose and time of nicaraven administration for mitigating the side effects of radiotherapy in a preclinical tumor-bearing mouse model
http://hdl.handle.net/10069/00041927
http://hdl.handle.net/10069/00041927b583b7fd-2612-4414-b197-a30c1649a706
名前 / ファイル | ライセンス | アクション |
---|---|---|
TARD16.pdf (2.3 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-12-05 | |||||
タイトル | ||||||
タイトル | Optimization on the dose and time of nicaraven administration for mitigating the side effects of radiotherapy in a preclinical tumor-bearing mouse model | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | DNA damage | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | fibrosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | inflammatory response | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | lung injury | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | radiation | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Xu, Yong
× Xu, Yong× Abdelghany, Lina× Sekiya, Reiko× Zhai, Da× Jingu, Keiichi× Li, Tao-Sheng |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objective: Radiation-induced lung injury (RILI) is one of the serious complications of radiotherapy. We have recently demonstrated that nicaraven can effectively mitigate RILI in healthy mice. Here, we further tried to optimize the dose and time of nicaraven administration for alleviating the side effects of radiotherapy in tumor-bearing mice. Methods and results: A subcutaneous tumor model was established in the back of the chest in C57BL/6N mice by injecting Lewis lung cancer cells. Therapeutic thoracic irradiations were done, and placebo or different doses of nicaraven (20, 50, 100 mg/kg) were administrated intraperitoneally pre-irradiation (at almost 5–10 min before irradiation) or post-irradiation (within 5 min after irradiation). Mice that received radiotherapy and nicaraven were sacrificed on the 30th day, but control mice were sacrificed on the 15th day. Serum and lung tissues were collected for evaluation. Nicaraven significantly decreased the level of CCL8, but did not clearly change the levels of 8-OHdG, TGF-β, IL-1β, and IL-6 in serum. Besides these, nicaraven effectively decreased the levels of TGF-β, IL-1β, and SOD2 in the lungs, especially by post-irradiation administration with the dose of 20 mg/kg. Although there was no significant difference, the expression of SOD1, 53BP1, and caspase 3 was detected lower in the lungs of mice received nicaraven post-irradiation than that of pre-irradiation. Conclusion: According to our data, the administration of nicaraven at a relatively low dose soon after radiotherapy will be recommended for attenuating the side effects of radiotherapy. |
|||||
書誌情報 |
Therapeutic Advances in Respiratory Disease 巻 16, p. 175346662211372, 発行日 2022 |
|||||
出版者 | ||||||
出版者 | SAGE Publications Ltd | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1753-4666 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1177/17534666221137277 | |||||
権利 | ||||||
権利情報 | © The Author(s), 2022. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Therapeutic Advances in Respiratory Disease, 16, art.no. 175346662211372; 2022 |